In the treatment of glioblastoma (GBM), this vaccine reshaped the tumor microenvironment by reducing the proportion of Treg cells, myeloid-derived suppressor cells (MDSCs), and microglial cells, while increasing the proportion of CD8+ T cells and tissue-resident memory T cells (TRMs) [67]. The gene discussed is CD8A; the disease is glioblastoma.